Thiazides and related diuretics
Drug Safety Update
January 2023: Xaqua (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations
November 2018: Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use
February 2016: Co-prescribing an ACE inhibitor or Angiotensin-II receptor antagonists with potassium sparing diuretics - risk of fatal hyperkalaemia
NICE guidance
NG136: Hypertension in adults: diagnosis and management
Local guidance
K&M ICB Prescribing Metolazone (Xaqua®) Position Statement
K&M ICB Metolazone (Xaqua®) Patient Information
| Pack |
|---|
| 28 tablet |
| 30 tablet |
| 56 tablet |
| 60 tablet |
| Pack |
|---|
| 30 tablet |
| Pack |
|---|
| 28 tablet |
| 500 tablet |
| Pack |
|---|
| 28 tablet |
| 500 tablet |
| 100 tablet |
| 1000 tablet |
| Pack |
|---|
| 28 tablet |
| 100 tablet |
| Pack |
|---|
| 28 tablet |
| 30 tablet |
| 100 tablet |
| 500 tablet |
Prescribe by brand. Metolazone should be initiated by Cardiology or Renal specialists as branded Xaqua® 5mg tablets. Must be prescribed by brand – should not be prescribed in generic form as this is non-formulary.
Please note: Xaqua 5mg is approximately equivalent to 10mg unlicensed metolazone, these products are not interchangeable. The starting dose for Xaqua should be 2.5mg daily.
Also refer to the drug safety update above for more information.
| Pack |
|---|
| 1 tablet |
| 50 tablet |
| 100 tablet |
| Pack |
|---|
| 1 tablet |
| Pack |
|---|
| 30 tablet |
| 1 tablet |
| 28 tablet |
| 100 tablet |
| Pack |
|---|
| 30 tablet |
| 1 tablet |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary